• Something wrong with this record ?

Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome

M. Arrigo, J. Parenica, E. Ganovska, M. Pavlusova, A. Mebazaa,

. 2019 ; 22 (-) : 174-176. [pub] 20190309

Language English Country Ireland

Document type Journal Article

Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had stepwise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 ± 10.6 vs. 27.6 ± 2.1 vs. 22.5 ± 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 ± 2.7 vs. 21.8 ± 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013219
003      
CZ-PrNML
005      
20190426132920.0
007      
ta
008      
190405s2019 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcha.2019.02.011 $2 doi
035    __
$a (PubMed)30906846
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Arrigo, Mattia $u Department of Cardiology, - University Hospital Zurich, Zurich, Switzerland.
245    10
$a Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome / $c M. Arrigo, J. Parenica, E. Ganovska, M. Pavlusova, A. Mebazaa,
520    9_
$a Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had stepwise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 ± 10.6 vs. 27.6 ± 2.1 vs. 22.5 ± 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 ± 2.7 vs. 21.8 ± 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Parenica, Jiri $u Department of Internal Medicine and Cardiology, - University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Ganovska, Eva $u Department of Internal Medicine and Cardiology, - University Hospital Brno, Brno, Czech Republic.
700    1_
$a Pavlusova, Marie $u Department of Internal Medicine and Cardiology, - University Hospital Brno, Brno, Czech Republic.
700    1_
$a Mebazaa, Alexandre $u INSERM UMR-S 942, Université Paris Diderot - PRES Sorbonne Paris Cité, Department of Anesthesiology and Critical Care Medicine - AP-HP Saint Louis and Lariboisière University Hospitals, Paris, France.
773    0_
$w MED00198717 $t International journal of cardiology. Heart & vasculature $x 2352-9067 $g Roč. 22, č. - (2019), s. 174-176
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30906846 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190426132957 $b ABA008
999    __
$a ind $b bmc $g 1392529 $s 1051524
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 22 $c - $d 174-176 $e 20190309 $i 2352-9067 $m International journal of cardiology Heart & vasculature $n Int J Cardiol Heart Vasc $x MED00198717
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...